The document summarizes the pharmaceutical industry in India. It notes that India has over 24,000 licensed pharmaceutical companies and is among the top 35 drug producers worldwide. The industry has grown significantly in recent decades from repackaging drugs to manufacturing many bulk drugs and generics. It is estimated the market will reach $40.18 billion by 2014 and $70.60 billion by 2019. While the industry faces some challenges like drug price controls, it is poised for continued growth due to factors like rising incomes, expansion in rural areas, and improvements in healthcare infrastructure.
This PPT contains complete analysis of Pharmaceutical Industry including worldwide and nationwide picture, leading organizations, SWOT analysis, Government policies and regulations, challenges and solutions.
The Indian markets and financial institutions stand out as sound, stable and better
regulated in contrast to developed economies. As a result, India can continue to be an
attractive market in view of its strong and stable fundamentals and the resilience which
Indian economy has displayed so far
“SWOT ANALYSIS OF NEW PHARMACEUTICAL COMPANY”Dharmik Bhatt
Main Objective
To find the Strength, weakness, Opportunities and threat of the company and all new pharmaceutical companies.
To find out the perception and expectation of doctors and retailers towards the new pharmaceutical company.
Sub Objectives
To find out the big player of the market (Tough Competitor).
To find the way for new pharmaceutical company from tough competition.
To create strategy for company with the help of research detail.
To analyze Vadodara market for company.
To create good communication bridge between new company to doctors and retailers, that full feel all require expectation of both.
This PPT contains complete analysis of Pharmaceutical Industry including worldwide and nationwide picture, leading organizations, SWOT analysis, Government policies and regulations, challenges and solutions.
The Indian markets and financial institutions stand out as sound, stable and better
regulated in contrast to developed economies. As a result, India can continue to be an
attractive market in view of its strong and stable fundamentals and the resilience which
Indian economy has displayed so far
“SWOT ANALYSIS OF NEW PHARMACEUTICAL COMPANY”Dharmik Bhatt
Main Objective
To find the Strength, weakness, Opportunities and threat of the company and all new pharmaceutical companies.
To find out the perception and expectation of doctors and retailers towards the new pharmaceutical company.
Sub Objectives
To find out the big player of the market (Tough Competitor).
To find the way for new pharmaceutical company from tough competition.
To create strategy for company with the help of research detail.
To analyze Vadodara market for company.
To create good communication bridge between new company to doctors and retailers, that full feel all require expectation of both.
Market research for Indian Pharmaceutical Market switching over from prescribed to OTC products. Scope of Indian Pharmaceutical OTC market, opportunities and challenges.
India is one of the emerging markets which is offering significant growth potential for the industry. This presentation provides a glance of Indian Pharmaceutical Market with more insights into Indian OTC drug markets, its current scenario as well as strategies for ensuring higher sales returns.
Trends & Opportunities for Indian Pharma is a knowledge paper highlighting the upcoming trends and related opportunities in Indian pharmaceuticals industry
Introduction Indian Pharmaceutical market, SWOT analysis, PEST Analysis, Timeline analysis of Sun Pharma, Glaxo Smith Kline, Mankind, CIPLA and Zydus Cadila.
Bangladesh Pharmaceuticals Market & It's Future (for non pharma background)
if you need the slide please call +8801717678894 or email: shadhin1008@live.com
Global Generic Pharmaceutical Market - Qualitative and Quantitative AnalysisAiswariya Chidambaram
This report was presented at the Pharma Tech 2013 Conference - India A Game Changer in the Pharma Industry at Ahmedabad, India in December 2013. The presentation highlights the overview of the global generic pharmaceuticals market, with particular focus on the key market trends and challenges by therapeutic areas and geographies including the U.S, EU and India. List of key blockbuster drugs scheduled to lose patent protection between 2010 and 2020 have been included. Additionally impact of regulation on generic drugs by region and strategic recommendations for the success of market participants are also covered in this report.
May 2015 Edition of BEACON, A Monthly Newsletter by SIMCON.
Inside this issue:
About Us
Our Team
INDUSTRY ANALYSIS : Pharmaceutical Industry
COMPANY ANALYSIS : Sun Pharma
BRAND ANALYSIS : Kellogg's
Concept of the month
I have to try to share some knowledge about the Indian health care sector. I have put some data to get more and more knowledge which can easily understand.
Present Status and Scope of Pharmaceutical industry in IndiaMadhuraNewrekar
The Indian pharmaceutical industry came into existence in 1901, when Bengal Chemical & Pharmaceutical Company started its maiden operation in Calcutta.
The next few decades saw the pharmaceutical industry moving through several phases, largely in accordance with government policies. The development, present status and scope of pharmaceutical industry in India.
Market research for Indian Pharmaceutical Market switching over from prescribed to OTC products. Scope of Indian Pharmaceutical OTC market, opportunities and challenges.
India is one of the emerging markets which is offering significant growth potential for the industry. This presentation provides a glance of Indian Pharmaceutical Market with more insights into Indian OTC drug markets, its current scenario as well as strategies for ensuring higher sales returns.
Trends & Opportunities for Indian Pharma is a knowledge paper highlighting the upcoming trends and related opportunities in Indian pharmaceuticals industry
Introduction Indian Pharmaceutical market, SWOT analysis, PEST Analysis, Timeline analysis of Sun Pharma, Glaxo Smith Kline, Mankind, CIPLA and Zydus Cadila.
Bangladesh Pharmaceuticals Market & It's Future (for non pharma background)
if you need the slide please call +8801717678894 or email: shadhin1008@live.com
Global Generic Pharmaceutical Market - Qualitative and Quantitative AnalysisAiswariya Chidambaram
This report was presented at the Pharma Tech 2013 Conference - India A Game Changer in the Pharma Industry at Ahmedabad, India in December 2013. The presentation highlights the overview of the global generic pharmaceuticals market, with particular focus on the key market trends and challenges by therapeutic areas and geographies including the U.S, EU and India. List of key blockbuster drugs scheduled to lose patent protection between 2010 and 2020 have been included. Additionally impact of regulation on generic drugs by region and strategic recommendations for the success of market participants are also covered in this report.
May 2015 Edition of BEACON, A Monthly Newsletter by SIMCON.
Inside this issue:
About Us
Our Team
INDUSTRY ANALYSIS : Pharmaceutical Industry
COMPANY ANALYSIS : Sun Pharma
BRAND ANALYSIS : Kellogg's
Concept of the month
I have to try to share some knowledge about the Indian health care sector. I have put some data to get more and more knowledge which can easily understand.
Present Status and Scope of Pharmaceutical industry in IndiaMadhuraNewrekar
The Indian pharmaceutical industry came into existence in 1901, when Bengal Chemical & Pharmaceutical Company started its maiden operation in Calcutta.
The next few decades saw the pharmaceutical industry moving through several phases, largely in accordance with government policies. The development, present status and scope of pharmaceutical industry in India.
What does good creative look like in the digital space? William Martino, SVP of Digital Strategy offers examples of "sustained" breakthrough and "disruptive" breakthrough across a variety of verticals
Cultivating Pharma Patient Relationships in the Digital EraPerficient, Inc.
Patients are more empowered than ever to be advocates for their own health, which has led to a dramatic shift in their expectations of pharmaceutical and medical device companies. Patients now expect these companies to provide them with the kind of personalized advice, support, and tools they used to only get from their physicians.
This shift has created a unique opportunity for life sciences organizations to develop a direct relationship with the consumers of their products. In this SlideShare, Param Singh, director of clinical operations solutions at Perficient, shows how organizations can use strategy, technology, and design to establish themselves as an integral part of a patient’s health.
Job of a Medical Representative is very challenging. They have to achieve their sales target by generating prescriptions in favor of their products.Here is the list of traits which are needed to become a successful Medical Representative is given below.
NEW ERA OF DRUG PRODUCT: OPPORTUNITIES AND CHALLENGESganpat420
Abstract
Introduction
Global pharmaceutical industry
Indian pharmaceutical industry
Indian Pharmaceutical Market
Opportunities
Challenges
Conclusion
References
3rd annual pharmaceutical leadership summit 2014 white paper Indian Affairs
It is widely believed that the consolidations in the Indian pharma sector is likely to continue, particularly among generic drug players and will drive shareholder value going forward.India-based pharmaceutical companies have majorly been absent from much of the recent M&A activities, partly because of their healthy growth outlooks. The global pharmaceutical industry will continue to undergo a pace of rapid consolidation to drive shareholder value; particularly in the case of companies seeking new growth platforms, against the backdrop of patent expirations.With many drugs going off patent in the US, Indian pharma companies would continue to experience strong growth in American market, indian pharma companies would continue to experience strong growth in the US over the medium-term. This would be driven by the sizable generic opportunity (drugs with brand value of $25-30 billion are expected to face generic competition) over the next 2-3 years. As one of the recently industrialized nations, India has a fast-growing economy as well as an ever-expanding, ever-urbanized population, however its healthcare system still has a lot of potential for development. To Western readers, analyzing a healthcare system in the East seems daunting. It takes some of us decades to master an understanding of the healthcare system of our origin country. Nevertheless, there are several methods to approaching another country’s system. These include the exposition of some invariant principles that apply across various contexts, the application of existing frameworks for healthcare system analysis, appraisal of the major transitions underway in the country, and an analysis of the country’s public health issues. India faces challenges in pursuing each of these goals. With regards to cost, at least 70% of all healthcare is frequently financed out-of-pocket by the population. There is little health insurance or other forms of risk pooling, little regulation and accountability of providers, and a predominance of fee-for-service payment, all of which are associated with high costs. There is also questionable efficiency of much of the state healthcare system, and a great distrust of the public sector. Against the backdrop of the above challenges, Pharmaleaders has lined up top industry experts, Pharma Academia, Ministry Officials, Government Representative, Policy Makers & Medical Professionals under one platform both in india & abroad to debate & deliberate the complex issues of the industry & give a meaningful discussion on the Brand India & Make In India concept. More than 300 professionals will be participating the mega event where professionals from Middle East, Africa, Europe, Lation America will also be attending.The historic 7th Annual Pharmaceutical Leadership Summit & Business Leadership Awards 2014 to be held in a uniquely positioned full day program encompassing two themes “Make In India – Healthcare Reforms , Insurance,Innovations,Investments & Infrastructur
Pharmaceutical market india a comprehensive industry analysis - Reports CornerReports Corner
"1.0 Summary
“Pharmaceutical Market: India, A Competitive Industry Analysis” by Kelly Scientific Publications is a comprehensive report on the pharmaceutical and biotechnology industry in India and its impact on international markets. This report scrutinises top Indian pharmacos and their battle within domestic and international therapeutic markets. The business environment in which they compete is analysed as are key drivers, constraints, challenges and opportunities.
The Indian pharmaceutical market is set to become the eight largest pharma market globally by 2015. In 2012 it was worth $13 billion. It is forecast to reach $50 billion by 2015 and increase its dominance as a leading player in Asia. It is predicted that the Indian pharma market will be a significant global competitor by 2020 with an expected worth of up to $74 billion.
This report describes the current therapeutics that are propelling the biopharmaceutical market in India. It examines the current economic climate and how India compares to other emerging markets and also evolved markets such as the US and Europe. Current developments relating to patent expirations, government funding, and regulations are discussed. The emerging trends that appear in key sub-markets such as generics, oncology, cardiovascular, diabetes and vaccines are elucidated and analysed.
This study reveals market figures of the overall Indian pharmaceutical market and sub-markets. Forecast projections and future growth rates are provided to give the reader a forthcoming perspective of this growing industry.
https://www.reportscorner.com/reports/15826/Pharmaceutical-Market:-India-A-Comprehensive-Industry-Analysis/
Implicitly or explicitly all competing businesses employ a strategy to select a mix
of marketing resources. Formulating such competitive strategies fundamentally
involves recognizing relationships between elements of the marketing mix (e.g.,
price and product quality), as well as assessing competitive and market conditions
(i.e., industry structure in the language of economics).
The world of search engine optimization (SEO) is buzzing with discussions after Google confirmed that around 2,500 leaked internal documents related to its Search feature are indeed authentic. The revelation has sparked significant concerns within the SEO community. The leaked documents were initially reported by SEO experts Rand Fishkin and Mike King, igniting widespread analysis and discourse. For More Info:- https://news.arihantwebtech.com/search-disrupted-googles-leaked-documents-rock-the-seo-world/
What is the TDS Return Filing Due Date for FY 2024-25.pdfseoforlegalpillers
It is crucial for the taxpayers to understand about the TDS Return Filing Due Date, so that they can fulfill your TDS obligations efficiently. Taxpayers can avoid penalties by sticking to the deadlines and by accurate filing of TDS. Timely filing of TDS will make sure about the availability of tax credits. You can also seek the professional guidance of experts like Legal Pillers for timely filing of the TDS Return.
What are the main advantages of using HR recruiter services.pdfHumanResourceDimensi1
HR recruiter services offer top talents to companies according to their specific needs. They handle all recruitment tasks from job posting to onboarding and help companies concentrate on their business growth. With their expertise and years of experience, they streamline the hiring process and save time and resources for the company.
Tata Group Dials Taiwan for Its Chipmaking Ambition in Gujarat’s DholeraAvirahi City Dholera
The Tata Group, a titan of Indian industry, is making waves with its advanced talks with Taiwanese chipmakers Powerchip Semiconductor Manufacturing Corporation (PSMC) and UMC Group. The goal? Establishing a cutting-edge semiconductor fabrication unit (fab) in Dholera, Gujarat. This isn’t just any project; it’s a potential game changer for India’s chipmaking aspirations and a boon for investors seeking promising residential projects in dholera sir.
Visit : https://www.avirahi.com/blog/tata-group-dials-taiwan-for-its-chipmaking-ambition-in-gujarats-dholera/
Skye Residences | Extended Stay Residences Near Toronto Airportmarketingjdass
Experience unparalleled EXTENDED STAY and comfort at Skye Residences located just minutes from Toronto Airport. Discover sophisticated accommodations tailored for discerning travelers.
Website Link :
https://skyeresidences.com/
https://skyeresidences.com/about-us/
https://skyeresidences.com/gallery/
https://skyeresidences.com/rooms/
https://skyeresidences.com/near-by-attractions/
https://skyeresidences.com/commute/
https://skyeresidences.com/contact/
https://skyeresidences.com/queen-suite-with-sofa-bed/
https://skyeresidences.com/queen-suite-with-sofa-bed-and-balcony/
https://skyeresidences.com/queen-suite-with-sofa-bed-accessible/
https://skyeresidences.com/2-bedroom-deluxe-queen-suite-with-sofa-bed/
https://skyeresidences.com/2-bedroom-deluxe-king-queen-suite-with-sofa-bed/
https://skyeresidences.com/2-bedroom-deluxe-queen-suite-with-sofa-bed-accessible/
#Skye Residences Etobicoke, #Skye Residences Near Toronto Airport, #Skye Residences Toronto, #Skye Hotel Toronto, #Skye Hotel Near Toronto Airport, #Hotel Near Toronto Airport, #Near Toronto Airport Accommodation, #Suites Near Toronto Airport, #Etobicoke Suites Near Airport, #Hotel Near Toronto Pearson International Airport, #Toronto Airport Suite Rentals, #Pearson Airport Hotel Suites
Buy Verified PayPal Account | Buy Google 5 Star Reviewsusawebmarket
Buy Verified PayPal Account
Looking to buy verified PayPal accounts? Discover 7 expert tips for safely purchasing a verified PayPal account in 2024. Ensure security and reliability for your transactions.
PayPal Services Features-
🟢 Email Access
🟢 Bank Added
🟢 Card Verified
🟢 Full SSN Provided
🟢 Phone Number Access
🟢 Driving License Copy
🟢 Fasted Delivery
Client Satisfaction is Our First priority. Our services is very appropriate to buy. We assume that the first-rate way to purchase our offerings is to order on the website. If you have any worry in our cooperation usually You can order us on Skype or Telegram.
24/7 Hours Reply/Please Contact
usawebmarketEmail: support@usawebmarket.com
Skype: usawebmarket
Telegram: @usawebmarket
WhatsApp: +1(218) 203-5951
USA WEB MARKET is the Best Verified PayPal, Payoneer, Cash App, Skrill, Neteller, Stripe Account and SEO, SMM Service provider.100%Satisfection granted.100% replacement Granted.
Enterprise Excellence is Inclusive Excellence.pdfKaiNexus
Enterprise excellence and inclusive excellence are closely linked, and real-world challenges have shown that both are essential to the success of any organization. To achieve enterprise excellence, organizations must focus on improving their operations and processes while creating an inclusive environment that engages everyone. In this interactive session, the facilitator will highlight commonly established business practices and how they limit our ability to engage everyone every day. More importantly, though, participants will likely gain increased awareness of what we can do differently to maximize enterprise excellence through deliberate inclusion.
What is Enterprise Excellence?
Enterprise Excellence is a holistic approach that's aimed at achieving world-class performance across all aspects of the organization.
What might I learn?
A way to engage all in creating Inclusive Excellence. Lessons from the US military and their parallels to the story of Harry Potter. How belt systems and CI teams can destroy inclusive practices. How leadership language invites people to the party. There are three things leaders can do to engage everyone every day: maximizing psychological safety to create environments where folks learn, contribute, and challenge the status quo.
Who might benefit? Anyone and everyone leading folks from the shop floor to top floor.
Dr. William Harvey is a seasoned Operations Leader with extensive experience in chemical processing, manufacturing, and operations management. At Michelman, he currently oversees multiple sites, leading teams in strategic planning and coaching/practicing continuous improvement. William is set to start his eighth year of teaching at the University of Cincinnati where he teaches marketing, finance, and management. William holds various certifications in change management, quality, leadership, operational excellence, team building, and DiSC, among others.
RMD24 | Retail media: hoe zet je dit in als je geen AH of Unilever bent? Heid...BBPMedia1
Grote partijen zijn al een tijdje onderweg met retail media. Ondertussen worden in dit domein ook de kansen zichtbaar voor andere spelers in de markt. Maar met die kansen ontstaan ook vragen: Zelf retail media worden of erop adverteren? In welke fase van de funnel past het en hoe integreer je het in een mediaplan? Wat is nu precies het verschil met marketplaces en Programmatic ads? In dit half uur beslechten we de dilemma's en krijg je antwoorden op wanneer het voor jou tijd is om de volgende stap te zetten.
Putting the SPARK into Virtual Training.pptxCynthia Clay
This 60-minute webinar, sponsored by Adobe, was delivered for the Training Mag Network. It explored the five elements of SPARK: Storytelling, Purpose, Action, Relationships, and Kudos. Knowing how to tell a well-structured story is key to building long-term memory. Stating a clear purpose that doesn't take away from the discovery learning process is critical. Ensuring that people move from theory to practical application is imperative. Creating strong social learning is the key to commitment and engagement. Validating and affirming participants' comments is the way to create a positive learning environment.
Falcon stands out as a top-tier P2P Invoice Discounting platform in India, bridging esteemed blue-chip companies and eager investors. Our goal is to transform the investment landscape in India by establishing a comprehensive destination for borrowers and investors with diverse profiles and needs, all while minimizing risk. What sets Falcon apart is the elimination of intermediaries such as commercial banks and depository institutions, allowing investors to enjoy higher yields.
LA HUG - Video Testimonials with Chynna Morgan - June 2024Lital Barkan
Have you ever heard that user-generated content or video testimonials can take your brand to the next level? We will explore how you can effectively use video testimonials to leverage and boost your sales, content strategy, and increase your CRM data.🤯
We will dig deeper into:
1. How to capture video testimonials that convert from your audience 🎥
2. How to leverage your testimonials to boost your sales 💲
3. How you can capture more CRM data to understand your audience better through video testimonials. 📊
Personal Brand Statement:
As an Army veteran dedicated to lifelong learning, I bring a disciplined, strategic mindset to my pursuits. I am constantly expanding my knowledge to innovate and lead effectively. My journey is driven by a commitment to excellence, and to make a meaningful impact in the world.
1. 1
Introduction::
The pharmaceutical industry is the world's largest industry due to worldwide revenues of
approximately US$2.8 trillion. Pharma industry has seen major changes in the recent
years that place new demands on payers, providers and manufacturers. Customers now
demand the same choice and convenience from pharma industry that they find in other
segment. Indian Pharmaceutical Industry is poised for high consistent growth over the
next few years, driven by a multitude of factors. Top Indian Companies like
Ranbaxy, Dr.Reddy's , CIPLA and Dabur have already established their
presence. Indian companies have only recently entered the area. The Indian
pharmaceutical industry came into existence in 1901, when Bengal Chemical &
Pharmaceutical Company started its maiden operation in Calcutta. The next few decades
saw the pharmaceutical industry moving through several phases, largely in accordance
with government policies. Commencing with repackaging and preparation of
formulations from imported bulk drugs, the Indian industry has moved on to become a
net foreign exchange earner, and has been able to underline its presence in the global
pharmaceutical arena as one of the top 35 drug producers worldwide. Currently, there are
more than 2,400 registered pharmaceutical producers in India. There are 24,000 licensed
pharmaceutical companies. Of the 465 bulk drugs used in India, approximately 425
are manufactured here. India has more drug-manufacturing facilities that have been
approved by the U.S. Food and Drug Administration than any country other than the US.
Indian generics companies supply 84% of the AIDS drugs that Doctors without Borders
uses to treat 60,000 patients in more than 30 countries. There can be several challenges
for pharma marketing with global channels opening up from all directions it has become
an art of its own kind.
As the fourth largest market in the Asia Pacific Region and an important player among
the fast growing pharmaceutical markets, India has also witnessed considerable growth in
its expansion activities with the establishment of IPR, rising middle class population,
emerging rural markets and improvement in medical infrastructure facilities. Amongst
the fast paced global market, Indian pharma market occupies a predominant position and
is the second fastest growing sector in India, after IT. The statistic shows that the
Compound Annual Growth Rate (CAGR) during 2004-08 for India’s pharmaceutical
market was 13.8 per cent. In view of the significant market growth, it is estimated that by
2014 and 2019, overall pharmaceutical sales will reach Rs 1539 bn (US$40.18 bn) and Rs
2648 bn (US$ 70.60 bn) respectively. A key requirement for growth is undeniably the
country’s booming economy and greater state involvement in the health sector.
Apart from the fast growing economy, India’s large, growing and ageing population is a
major attraction for pharmaceutical firms. According to the UN Population Division, the
number of people living in the country will increase from 1.04 bn in 2000 to 1.41 bn in
2020 – a rise of 36 per cent At the same time, the population aged 65 and over will
increase from 4.3 per cent to 6.3 per cent over the same period, though the
pharmaceutical expenditure in 2009 was 1.24 per cent of GDP, which is just below the
global average of 1.40 per cent. The inevitable growth of pharmaceutical sector in the
country is vivid from the above factors.
2. 2
The Indian Pharmaceutical industry is highly fragmented with about 24,000 players
(around 330 in the organized sector). The top ten companies make up for more than a
third of the market. The Indian pharma industry (IPM) grew by 16% YoY in 2012 to `
629 bn. It accounts for about 1.4% of the world's pharma industry in value terms and
10% in volume terms.
Besides the domestic market, Indian pharma companies also have a large chunk of their
revenues coming from exports. While some are focusing on the generics market in the
US, Europe and semi-regulated markets, others are focusing on custom manufacturing for
innovator companies. Biopharmaceuticals is also increasingly becoming an area of
interest given the complexity in manufacture and limited competition.
The drug price control order (DPCO) continues to be a menace for the industry. There are
three tiers of regulations – on bulk drugs, on formulations and on overall profitability.
This has made the profitability of the sector susceptible to the whims and fancies of the
pricing authority. In connotation, with pricing policy of 354 drugs,NLEM (National list
of essential medicines) was released, which covered the list of the drugs which the
authority intends to put under price control. The policy has been stiffly opposed by the
pharmaceutical industry.
Introduction of GDUFA (Generic drug user fee Act) in US. As per this act, the generic
companies are required to pay user fees to USFDA, for application of drugs and
manufacturing facilities. This fee will be utilized by USFDA to engage additional
resources in order to reduce current and pending applications and speed up the approval
process. (Note: This act was passed in 2011, which was signed into Law in July 2012).
The R&D spends of the top five companies is about 5% to 10% of revenues. This ratio is
still way below the global average of 15% to 20% of sales. Indian companies have
adopted various strategies for their R&D efforts. Some have entered into collaboration
and partnership agreements with innovator companies; others have out-licensed their
molecules for milestone payments. Hiving off R&D units into separate companies has
also become a preferred option for many Indian pharma players. That said, given that the
research pipelines of Big Pharma are drying up, they have now begun to dabble in
generics. In this regard, these innovator companies are either buying out Indian firms or
are forging alliances with them.
Objectives::
The objective of the study is find problem and prospect of medical product selling of
Dankuni Regeion with the help sample of 50 no of sales staff and some doctors &
suppliers.
Study area::
Different studies have been done on problem & prospects medical products selling
previously. The present investigation has been carried out at Dankuni Region of west
3. 3
Bengal with the help of 50 no of sales staff (GSK Ltd) and some doctors & suppliers. .
For proper and orderly study the selected salesmen are asked to give their views.
Methodlogy::
The present study was a descriptive research conducted between Dec-2012-Feb
2013(3months).The study comprises on some selected open-ended & close-ended
questions to 50 no of sales people of age group between 30 - 56 years and some doctors
& supplier of selected questions (Table 1).
Table 1::
Sales people::
1. How many customers do you meet every day?
2. What types of medicine do you sell every day?
3. What do you think about your profession?
4. What is the level of satisfaction you have got in this profession?
5. Do you find any future in this profession?
6. What is your food habit during working time?
7. What types of behavior do you expect from the customer (Doctors &
Distributors)?
8. What types of behavior do you got from them?
9. Does this profession create any problems regarding your family matter?
Company::
1. Are you satisfied with your salary?
2. What is your boss first reaction when you failed to achieve target?
3. What is your reaction in perspective of your boss’s reaction?
Suppliers::
1. Do you face any problems regarding supply of product as per sales people
Commitments?
2. Do you think sales people are satisfied with their job?
3. What types of behavior do you got from them?
Doctors::
1. What types of behavior do you got from the sales people?
2. Are think that they are satisfied with their job?
3. What is your first reaction when you meet with the sales people?
4. 4
Sample size::
N=50 (Where n= No of Respondents)
The primary data collect from 50 no of sales people of GSK Ltd of age group between 30
- 56 years and some doctors & supplier doctors to present the entire profession of
Dankuni Region of W.B.
Data collection::
Data collection is done in one stage with face to face conversation and over telephone. Of
50 no of sales people of age group between 30 - 56 years and some doctors & supplier
doctors of Dankuni Region of W.B. of GSK Ltd.
Discussion::
The study tells that the sales people of GSK Ltd are visit average 18 persons (Dr.-
11/Chemist-6/Store-1) every day as per data. They sell different types of medicine like
Paracetamol, Calcium & Health drink ( Horliks). Maximum people (70%) are enjoy their
work while few (20%) are not happy with their profession and some of them(10%) trying
for substitute work according to their qualification. More than 30% people sometimes get
tired due to busy scheduled and heavy pressure of target and some times get depressed.
Maximum time they don’t give much time for food and can’t maintain proper fooding
habit. More than 80% people think that there is a good future in this profession. They eat
light food like fruit, fruit, juice, biscuits & sandwiches. They don’t like to take heavy
food during their visit. They expect good behavior from the customer but get average
behavior from them (77%). More than 45% sales people think that selling profession
create a problem in their family life but maximum people don’t think like that.
Maximum people (80%) are satisfied with their income (Salary + Incentives).When they
don’t achieve their target the team leader try to find out the problem and give proper
solution for that. Sometime get angry with them but most of the time help them according
to their expectation.
Maximum supplier(79%) are very much satisfied regarding supply of the medicine and
get medicine according to their(sales people) commitment. They think that maximum
(74%) sales people are satisfied with their job and try to maintained good behavior with
them (supplier).
Doctor’s thinks (60%) Sales people are very much professional and intelligent people and
maintained good behavior with them. Doctor thinks that the maximum sales people are
satisfied with their job but sometime get board due to repetitive work in nature.47%
doctor don’t like to attend to many sales call and try to maintained good behavior with
them.
5. 5
Conclution::
FY12/CY11 was a challenging on domestic front. The companies witnessed a sluggish
growth in the 1HFY12, on the back of severe competition in the acute segment.
Increasing competition from MNCs and unlisted companies impaired the growth of local
players. Though the Indian Pharma Industry grew by 16% vs 18% in FY11, large part of
the growth was contributed by the chronic segment.
MNC pharma companies continued to excel during FY12/CY11. Of the 25 top selling
brands, 13 were from the MNCs. On the margin front, performance was not good. Most
of the companies saw increase in raw material and employee costs. Companies continued
to increase their MR strength and expand their reach to rural areas.
In the US, generic companies witnessed robust growth, as billion dollar products
like, Lipitor, Zyprexa, Plavix came off patent. On the other hand Europe continued to
face pressure.
Rupee depreciation was one important aspect which helped the industry. Many
companies benefited due to rupee depreciation, especially the companies who had not
hedged their receivables.
Many companies had received warning letters from the USFDA in the past. The year saw
some green signals from US regulator. While Aurobindo, Cadila and Claris got USFDA
clearances, Ranbaxy entered into a consent decree with USFDA in order to gets its two
manufacturing facilities re-approved by the US authorities.
The product patents regime heralds an era of innovation and research resulting in the
launch of new patented product launches. In the longer run, domestic companies would
face fresh competition from MNCs, as they would make aggressive new launches.
However, the latter would most likely be subject to price negotiation.
Drugs having estimated sales of over US$ 80 bn are expected to go off patent between
CY12 and CY15. With the governments in the developed markets looking to cut down
healthcare costs by facilitating a speedy introduction of generic drugs into the market,
domestic pharma companies will stand to benefit. However, despite this huge promise,
intense competition and consequent price erosion would continue to remain a cause for
concern.
The developing markets viz; Brazil, Turkey, Mexico, Russia etc are expected to witness
growth of around 25% during 2014-15. Like India, emerging markets are also “Branded”
by nature, thus Indian companies are well poised to capitalise on the opportunities in
these markets as well.
The life style segments such as cardiovascular, anti-diabetes, anti-depressants and anti-
cancers will continue to be lucrative and fast growing owing to increased urbanization
and change in lifestyle patterns. High growth in domestic sales in the future will depend
on the ability of companies to align their product portfolio towards the chronic segment
6. 6
as the lifestyle diseases like hypertension, congestive heart failure, depression, asthma,
and diabetes are on the rise.
Contract manufacturing and research (CRAMS) is expected to gain momentum going
forward. India’s competitive strengths in research services include English-language
competency, availability of low cost skilled doctors and scientists, large patient
population with diverse disease characteristics and adherence to international quality
standards. As for contract manufacturing, both global innovators and generic majors are
finding it profitable to outsource production. Although the scenario has yet not improved
for this space after the financial crisis, it is expected to improve going forward as the
pressure to prune costs increases.
As per the McKinsey report, Indian pharmaceuticals market is expected to grow to
US$ 55 bn in 2020 and has a potential to reach US$ 70 bn by 2020.
As the sales division and the sales person are the back bone of the company and all the
planning are failed if they failed not only that the problem and prospects of the
pharmaceutical industries are very much affecting the sales man life and the company
policy as we discuss above. From that above discussion and on the basis of discussion of
questioner we get following problem & prospects of medical products selling:
Problems::
• Loneliness can be a problem for medical sales representatives, who are often
away from their home base for long periods of time. In spite of the rewards, this
can be a very stressful job, with some reps experiencing burnout after some years
in the role.
• The working day is often extended by travel, which has the potential to disrupt
domestic routine and family and social life. However, many appreciate getting to
know their customers in social settings and enjoy the benefits of corporate
entertainment.
• Travel within a working day is frequent, absence from home at night is
occasional and overseas work or travel is uncommon.
• Food habits & family life create problem.
Prospects::
• Range of typical starting salaries: 18,000 – 24,000 (salary data collected Jan
13).
• Range of salaries with three to five years' experience: 25,000 – 35,000 (salary
data collected Jan 13).
• Range of salaries at senior levels: 30,000 – 55,000 (salary data collected Jan
13).
7. 7
• The range of salaries varies according to level and experience. Successful sales
staff can achieve high earnings consisting of a basic salary supplemented with
performance-related pay.
• Many companies offer other incentives and benefits such as a quality company
car, private health insurance, holidays abroad and similar rewards.
• Working hours typically include regular extra hours, but not weekends or shifts.
The car is a mobile office, but a room at home is also necessary for storing
promotional products and samples.
• Self-employment/freelance work is not possible. It may be possible to offer a
service to companies launching new products and wanting extra coverage, though
this requires a lot of contacts.
• The prospects for re-employment after a career break are good. Part-time work is
possible.
• Opportunities occur throughout the UK, but the job usually involves
responsibility for a particular geographical area. Good sales staff may find
themselves head-hunted from one company/region to another.
• One can rise from the position of a medical representative depending on his
caliber to higher positions in sales division or can enter into marketing
division.
References::
1. http://www.wikipedia.org.
2. http://www.google.co.in.
3. McKinsey consultancy.
4. The Indian Pharmaceutical Industry, Feb2012, ICRA.
5. The International Pharmaceutical Industry, Feb2012, ICRA.
6. http://www.iitk.ac.in.
7. GSK Sales people.